Adjuvant Therapy for Pancreatic Adenocarcinoma—Leaving No Rock Unturned
Menée à partir de données portant sur 1 132 patients atteints d'un adénocarcinome du pancréas ayant reçu une chimiothérapie à base de plusieurs agents thérapeutiques avant résection (âge moyen : 63,5 ans), cette étude de cohorte rétrospective évalue l'association entre une chimiothérapie adjuvante et la survie globale
Several randomized trials have established that the use of systemic chemotherapy in the multimodality treatment of patients with pancreatic ductal adenocarcinoma (PDAC) is associated with a substantial survival benefit. Recently, the PRODIGE trial demonstrated the superiority of modified FOLFIRINOX over single-agent gemcitabine as adjuvant therapy after pancreatectomy. National Comprehensive Cancer Network guidelines currently recommend multiagent regimens as preferred for the postoperative treatment of patients with PDAC. However, neoadjuvant therapy is now an established standard for patients with borderline resectable disease because it improves overall resection rates, R0 resection, and survival. It is also being increasingly used in the management of patients with PDAC presenting with potentially resectable disease. Yet, one area of ambiguity is whether there is a survival benefit associated with the administration of adjuvant chemotherapy in patients who have already received neoadjuvant treatment.
JAMA Oncology , éditorial, 2021